Ansa Biotechnologies partners with TeselaGen Biotechnology to enable commercial production of DNA products

Share Article

Ansa Biotechnologies Inc., the company developing a new way to make DNA using enzymes, is announcing a partnership with TeselaGen Biotechnology Inc., the company developing an integrated enterprise software operating system for designing, building, and optimizing biological and biochemical products.

Next-gen DNA synthesis using enzymes

TeselaGen has demonstrated a robust, scalable, and easy-to-use platform that we can trust as a cornerstone of our DNA manufacturing processes

Ansa Biotechnologies Inc., the company developing a new way to make DNA using enzymes, is announcing a partnership with TeselaGen Biotechnology Inc., the company developing an integrated enterprise software operating system for designing, building, and optimizing biological and biochemical products. The partnership will bring a broad set of tools to Ansa Biotechnologies that will bolster R&D workflows and enable early-stage DNA manufacturing.

“We are very excited about this new partnership. Ansa is at the forefront of enzymatic DNA synthesis and contributing to their success will keep fueling innovation in the biotech industry, empowering a new generation of companies to develop biological systems and sustainable bioproducts much faster and at a lower cost,” said Eduardo Abeliuk, CEO of TeselaGen. Michael Fero, COO at TeselaGen added, “Biotechnology is an information technology, and companies are moving away from burning large amounts of precious time and capital to build bespoke systems that are quickly obsolete and are difficult to maintain. Our secure and scalable enterprise systems are helping folks at companies ranging from the Fortune 50 to hot startups like Ansa save years of development time.”

“We believe in partnering with best-in-class service providers that are aligned with our mission to accelerate biotech research and development,” said Daniel Arlow, CEO at Ansa Biotechnologies. “TeselaGen has demonstrated a robust, scalable, and easy-to-use platform that we can trust as a cornerstone of our DNA manufacturing processes,” added George McArthur, Head of Product at Ansa Biotechnologies.

As part of this partnership, Ansa will license TeselaGen’s platform and have access to its end-to-end solution for designing and optimizing industrial-scale workflows. With the addition of Ansa to TeselaGen’s select group of partners, TeselaGen will also gain access to valuable product feedback that will guide the development of new features for defining and executing high throughput, high content workflows. The collaboration between Ansa Biotechnologies and TeselaGen Biotechnology will take effect immediately.

About Ansa Biotechnologies
Ansa Biotechnologies is building a faster and cheaper DNA synthesis service to accelerate synthetic biology research. Ansa’s core technology is a novel DNA synthesis method based on enzymes that will be faster, cleaner, and more accurate than existing methods. The unique approach, developed by the founders at UC Berkeley, uses an engineered template-independent polymerase conjugated to a single nucleoside triphosphate molecule to rapidly build a DNA sequence one base at a time. For more information, visit ansabio.com or follow on Twitter and LinkedIn.

About TeselaGen Biotechnology
TeselaGen is building an artificial intelligence-powered enterprise platform for designing, building, testing, and optimizing biological systems. TeselaGen's cloud-based platform bridges the gap between good ideas and the realization of valuable products like vaccines, biologic medicines, and sustainably sourced chemicals. TeselaGen is privately held and is based in the software hub of San Francisco, CA. The company has received early recognition in the form of four US National Science Foundation funding awards, a US Department of Energy funding award, CORFO awards, and a Bio-IT World Best Practices Award. TeselaGen uses its proprietary Synthetic Evolution® technology for efficient rapid prototyping and editing of recombinant molecules. Follow TeselaGen on Twitter and LinkedIn and learn more at teselagen.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Michael Fero

George McArthur
@TeselaGen
Follow >
Visit website